Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
Annamaria Brioli(Universitätsmedizin Greifswald), Michael Lauseker(Zimmer Biomet (Germany)), Ulla Olsson‐Strömberg(Uppsala University Hospital), Susanne Saußele(University of Mannheim), Alexander Kiani(Bayreuth Medical Center), Elke Dammann(Medizinische Hochschule Hannover), Tomasz Sacha, Edgar Faber(University Hospital Olomouc), Fausto Castagnetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Krzysztof Lewandowski(Poznan University of Medical Sciences), Andreas Hochhaus(Jena University Hospital), Klaus Hirschbühl(University of Augsburg), Philipp Ernst(Jena University Hospital), Peter Anhut(Praxis für Hämatologie und Onkologie), Elżbieta Patkowska(Institute for Transfusion Medicine), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Aleksandra Gołoś(Copernicus Memorial Hospital), Edyta Paczkowska(Pomeranian Medical University), Stefan W. Krause(Universitätsklinikum Erlangen), Elza Lomaia(Federal Almazov North-West Medical Research Centre), Franck E. Nicolini(Université Claude Bernard Lyon 1), Justyna Gil(Lublin Oncology Center), Christian Fabisch(Jena University Hospital), Han Bao(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Thomas Südhoff(Klinikum Passau), Sonja Heibl(Klinikum Wels-Grieskirchen), Anne Parry(Centre Hospitalier Annecy Genevois), Georg‐Nikolaus Franke(University Hospital Leipzig), Jiří Mayer(Central European Institute of Technology), Elena Morozova(First Pavlov State Medical University of St. Petersburg), Astghik Voskanyan(Heidelberg University), Hana Klamová(Institute of Haematology and Blood Transfusion)
Cited by 3
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564